NSCLC患者-话题@MedSci

#NSCLC患者#

171篇内容 | 3004人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1410942, encodeId=ad691410942b5, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=Clin Cancer Res：纳武单抗加用多西他赛可显著延长ICI初治NSCLC患者的生存期, objectType=article, longId=737804, objectId=dbf0e37804ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbf0e37804ff, replyNumber=0, likeNumber=90, createdTime=2022-09-06, rootId=0, userName=xiongliangxl, userId=06332789533, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbf0e37804ff, moduleTitle=Clin Cancer Res：纳武单抗加用多西他赛可显著延长ICI初治NSCLC患者的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbf0e37804ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410939, encodeId=3173141093980, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=Thorac Cancer：EGFR敏感突变NSCLC患者一线阿法替尼，吉非替尼或厄洛替尼治疗的生存获益比较, objectType=article, longId=728900, objectId=2d14e28900af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d14e28900af, replyNumber=0, likeNumber=0, createdTime=2022-06-10, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d14e28900af, moduleTitle=Thorac Cancer：EGFR敏感突变NSCLC患者一线阿法替尼，吉非替尼或厄洛替尼治疗的生存获益比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d14e28900af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410938, encodeId=282c1410938ac, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=ASCO：血清IL-8和IL-6水平作为黑色素瘤和NSCLC患者对免疫检查点抑制剂反应的预测因素, objectType=article, longId=728275, objectId=a347e2827567, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a347e2827567, replyNumber=0, likeNumber=81, createdTime=2022-06-01, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a347e2827567, moduleTitle=ASCO：血清IL-8和IL-6水平作为黑色素瘤和NSCLC患者对免疫检查点抑制剂反应的预测因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a347e2827567)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410940, encodeId=f00a1410940fd, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=J Clin Oncol：国产三代EGFR-TKI阿美替尼挺进晚期EGFR突变NSCLC患者一线治疗, objectType=article, longId=727759, objectId=e5e5e27759c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5e5e27759c4, replyNumber=0, likeNumber=84, createdTime=2022-05-26, rootId=0, userName=xiongliangxl, userId=06332789533, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5e5e27759c4, moduleTitle=J Clin Oncol：国产三代EGFR-TKI阿美替尼挺进晚期EGFR突变NSCLC患者一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5e5e27759c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410937, encodeId=3925141093e9e, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=J Clin Oncol：阿美替尼有望成为EGFR突变的NSCLC患者的一线疗法, objectType=article, longId=727709, objectId=f4e9e2770970, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4e9e2770970, replyNumber=0, likeNumber=105, createdTime=2022-05-25, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4e9e2770970, moduleTitle=J Clin Oncol：阿美替尼有望成为EGFR突变的NSCLC患者的一线疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4e9e2770970)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410935, encodeId=1de7141093583, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=Thorac Cancer:淋巴结阳性(cN+)和阴性(cN0)的I期NSCLC患者术后无病生存(DFS)差异, objectType=article, longId=727693, objectId=a4d6e2769330, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a4d6e2769330, replyNumber=0, likeNumber=71, createdTime=2022-05-25, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a4d6e2769330, moduleTitle=Thorac Cancer:淋巴结阳性(cN+)和阴性(cN0)的I期NSCLC患者术后无病生存(DFS)差异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a4d6e2769330)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410936, encodeId=9c1114109363f, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=Thorac Cancer：真实世界中晚期NSCLC患者伴有KRAS、MET、FGFR、RET、BRAF和HER2改变时一线使用免疫检查点抑制剂(ICIs)的疗效, objectType=article, longId=727690, objectId=5f10e2769003, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f10e2769003, replyNumber=0, likeNumber=62, createdTime=2022-05-25, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f10e2769003, moduleTitle=Thorac Cancer：真实世界中晚期NSCLC患者伴有KRAS、MET、FGFR、RET、BRAF和HER2改变时一线使用免疫检查点抑制剂(ICIs)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f10e2769003)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410934, encodeId=42c5141093426, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=Thorac Cancer：多中心回顾性研究评估dacomitinib（达可替尼）再挑战EGFR突变NSCLC患者的疗效, objectType=article, longId=727665, objectId=42bae2766592, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42bae2766592, replyNumber=0, likeNumber=77, createdTime=2022-05-25, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42bae2766592, moduleTitle=Thorac Cancer：多中心回顾性研究评估dacomitinib（达可替尼）再挑战EGFR突变NSCLC患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=42bae2766592)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410933, encodeId=274b14109338f, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=Thorac Cancer：EGFR阳性老年NSCLC患者吉非替尼进展后单药联合继续吉非替尼可改善患者PFS, objectType=article, longId=727473, objectId=6721e274735c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6721e274735c, replyNumber=0, likeNumber=105, createdTime=2022-05-22, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6721e274735c, moduleTitle=Thorac Cancer：EGFR阳性老年NSCLC患者吉非替尼进展后单药联合继续吉非替尼可改善患者PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6721e274735c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410941, encodeId=1724141094103, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=Thorac Cancer：ALK阳性晚期NSCLC患者克唑替尼进展后不同治疗模式的疗效, objectType=article, longId=727467, objectId=fe0ae2746739, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe0ae2746739, replyNumber=0, likeNumber=0, createdTime=2022-05-22, rootId=0, userName=xiongliangxl, userId=06332789533, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe0ae2746739, moduleTitle=Thorac Cancer：ALK阳性晚期NSCLC患者克唑替尼进展后不同治疗模式的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe0ae2746739)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410931, encodeId=d9a31410931d7, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=2022 AACR：ORR超60%，本土创新药谷美替尼有望为METex14跳跃突变NSCLC患者带来全新治疗选择！, objectType=article, longId=724037, objectId=8223e24037e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8223e24037e2, replyNumber=0, likeNumber=105, createdTime=2022-04-13, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8223e24037e2, moduleTitle=2022 AACR：ORR超60%，本土创新药谷美替尼有望为METex14跳跃突变NSCLC患者带来全新治疗选择！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8223e24037e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410932, encodeId=25e214109321a, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=AACR重磅之GLORY试验：SCC244对携带MET 14外显子跳变（METex14）的NSCLC患者的II期研究, objectType=article, longId=723990, objectId=9450e23990da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9450e23990da, replyNumber=0, likeNumber=69, createdTime=2022-04-12, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9450e23990da, moduleTitle=AACR重磅之GLORY试验：SCC244对携带MET 14外显子跳变（METex14）的NSCLC患者的II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9450e23990da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410930, encodeId=67a51410930cb, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=AACR重磅之INSIGHT研究：特泊替尼+吉非替尼联合治疗显著改善了伴有MET扩增的EGFR突变阳性NSCLC患者无进展生存期和总生存期, objectType=article, longId=723968, objectId=3207e2396893, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3207e2396893, replyNumber=0, likeNumber=117, createdTime=2022-04-12, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3207e2396893, moduleTitle=AACR重磅之INSIGHT研究：特泊替尼+吉非替尼联合治疗显著改善了伴有MET扩增的EGFR突变阳性NSCLC患者无进展生存期和总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3207e2396893)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410929, encodeId=8b451410929eb, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=AACR重磅之KEYNOTE-042：帕博丽珠单抗持续延长了中国晚期/转移性PD-L1阳性NSCLC患者的生存期——Keynote-042中国研究的4年随访数据结果, objectType=article, longId=723967, objectId=4b52e23967b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b52e23967b8, replyNumber=0, likeNumber=76, createdTime=2022-04-12, rootId=0, userName=xiongliangxl, userId=06332789533, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b52e23967b8, moduleTitle=AACR重磅之KEYNOTE-042：帕博丽珠单抗持续延长了中国晚期/转移性PD-L1阳性NSCLC患者的生存期——Keynote-042中国研究的4年随访数据结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4b52e23967b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410928, encodeId=4dc81410928f2, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=Front Oncol：真实世界评估PD-L1≧50%的晚期NSCLC患者一线pembrolizumab（帕博利珠单抗）单药治疗的长期疗效, objectType=article, longId=301707, objectId=d31c301e07bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d31c301e07bd, replyNumber=0, likeNumber=65, createdTime=2022-03-28, rootId=0, userName=xiongliangxl, userId=06332789533, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d31c301e07bd, moduleTitle=Front Oncol：真实世界评估PD-L1≧50%的晚期NSCLC患者一线pembrolizumab（帕博利珠单抗）单药治疗的长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d31c301e07bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410927, encodeId=fc83141092e65, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=BMC Cancer：不能切除的III期NSCLC患者cCRT后接受durvalumab维持治疗的血液学检查变化, objectType=article, longId=301652, objectId=9f863016522e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f863016522e, replyNumber=0, likeNumber=64, createdTime=2022-03-27, rootId=0, userName=xiongliangxl, userId=06332789533, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f863016522e, moduleTitle=BMC Cancer：不能切除的III期NSCLC患者cCRT后接受durvalumab维持治疗的血液学检查变化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f863016522e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410926, encodeId=8cd51410926e1, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=Radiology：术前脑MRI分期对IA期无症状NSCLC患者预后没有影响, objectType=article, longId=301235, objectId=97f9301235f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97f9301235f7, replyNumber=0, likeNumber=84, createdTime=2022-03-21, rootId=0, userName=xiongliangxl, userId=06332789533, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97f9301235f7, moduleTitle=Radiology：术前脑MRI分期对IA期无症状NSCLC患者预后没有影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97f9301235f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410925, encodeId=d1451410925ea, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=Oncologist：全球多中心真实世界探索EGFR-TKIs治疗罕见EGFR突变NSCLC患者的疗效, objectType=article, longId=300760, objectId=f451300e604a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f451300e604a, replyNumber=0, likeNumber=77, createdTime=2022-03-16, rootId=0, userName=xiongliangxl, userId=06332789533, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f451300e604a, moduleTitle=Oncologist：全球多中心真实世界探索EGFR-TKIs治疗罕见EGFR突变NSCLC患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f451300e604a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410924, encodeId=837714109245c, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=Ther Adv Med Oncol：北京协和医院团队真实世界探索HER2改变的晚期NSCLC患者更佳一线治疗方案, objectType=article, longId=300517, objectId=5c7c30051ed6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c7c30051ed6, replyNumber=0, likeNumber=92, createdTime=2022-03-13, rootId=0, userName=xiongliangxl, userId=06332789533, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c7c30051ed6, moduleTitle=Ther Adv Med Oncol：北京协和医院团队真实世界探索HER2改变的晚期NSCLC患者更佳一线治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c7c30051ed6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1410923, encodeId=ae10141092315, content=<a href='/topic/show?id=a4ed130e7d0' target=_blank style='color:#2F92EE;'>#NSCLC患者#</a>, objectTitle=Target Oncol:吴一龙教授IIIb期研究关注近真实世界中afatinib(阿法替尼)治疗EGFR突变阳性NSCLC患者的疗效, objectType=article, longId=295658, objectId=04a8295658c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04a8295658c9, replyNumber=0, likeNumber=65, createdTime=2022-02-16, rootId=0, userName=xiongliangxl, userId=06332789533, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04a8295658c9, moduleTitle=Target Oncol:吴一龙教授IIIb期研究关注近真实世界中afatinib(阿法替尼)治疗EGFR突变阳性NSCLC患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04a8295658c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

NSCLC患者

2020-05-29

xiongliangxl (审核中...)

前往app查看评论内容

#NSCLC患者#

Clin Cancer Res：纳武单抗加用多西他赛可显著延长ICI初治NSCLC患者的生存期

2022-09-06

hb2008ye (审核中...)

前往app查看评论内容

#NSCLC患者#

Thorac Cancer：EGFR敏感突变NSCLC患者一线阿法替尼，吉非替尼或厄洛替尼治疗的生存获益比较

2022-06-10

hb2008ye (审核中...)

前往app查看评论内容

#NSCLC患者#

ASCO：血清IL-8和IL-6水平作为黑色素瘤和NSCLC患者对免疫检查点抑制剂反应的预测因素

2022-06-01

xiongliangxl (审核中...)

前往app查看评论内容

#NSCLC患者#

J Clin Oncol：国产三代EGFR-TKI阿美替尼挺进晚期EGFR突变NSCLC患者一线治疗

2022-05-26

hb2008ye (审核中...)

前往app查看评论内容

#NSCLC患者#

J Clin Oncol：阿美替尼有望成为EGFR突变的NSCLC患者的一线疗法

2022-05-25

hb2008ye (审核中...)

前往app查看评论内容

#NSCLC患者#

Thorac Cancer:淋巴结阳性(cN+)和阴性(cN0)的I期NSCLC患者术后无病生存(DFS)差异

2022-05-25

hb2008ye (审核中...)

前往app查看评论内容

#NSCLC患者#

Thorac Cancer：真实世界中晚期NSCLC患者伴有KRAS、MET、FGFR、RET、BRAF和HER2改变时一线使用免疫检查点抑制剂(ICIs)的疗效

2022-05-25

hb2008ye (审核中...)

前往app查看评论内容

#NSCLC患者#

Thorac Cancer：多中心回顾性研究评估dacomitinib（达可替尼）再挑战EGFR突变NSCLC患者的疗效

2022-05-25

hb2008ye (审核中...)

前往app查看评论内容

#NSCLC患者#

Thorac Cancer：EGFR阳性老年NSCLC患者吉非替尼进展后单药联合继续吉非替尼可改善患者PFS

2022-05-22

xiongliangxl (审核中...)

前往app查看评论内容

#NSCLC患者#

Thorac Cancer：ALK阳性晚期NSCLC患者克唑替尼进展后不同治疗模式的疗效

2022-05-22

hb2008ye (审核中...)

前往app查看评论内容

#NSCLC患者#

2022 AACR：ORR超60%，本土创新药谷美替尼有望为METex14跳跃突变NSCLC患者带来全新治疗选择！

2022-04-13

hb2008ye (审核中...)

前往app查看评论内容

#NSCLC患者#

AACR重磅之GLORY试验：SCC244对携带MET 14外显子跳变（METex14）的NSCLC患者的II期研究

2022-04-12

hb2008ye (审核中...)

前往app查看评论内容

#NSCLC患者#

AACR重磅之INSIGHT研究：特泊替尼+吉非替尼联合治疗显著改善了伴有MET扩增的EGFR突变阳性NSCLC患者无进展生存期和总生存期

2022-04-12

xiongliangxl (审核中...)

前往app查看评论内容

#NSCLC患者#

AACR重磅之KEYNOTE-042：帕博丽珠单抗持续延长了中国晚期/转移性PD-L1阳性NSCLC患者的生存期——Keynote-042中国研究的4年随访数据结果

2022-04-12

xiongliangxl (审核中...)

前往app查看评论内容

#NSCLC患者#

Front Oncol：真实世界评估PD-L1≧50%的晚期NSCLC患者一线pembrolizumab（帕博利珠单抗）单药治疗的长期疗效

2022-03-28

xiongliangxl (审核中...)

前往app查看评论内容

#NSCLC患者#

BMC Cancer：不能切除的III期NSCLC患者cCRT后接受durvalumab维持治疗的血液学检查变化

2022-03-27

xiongliangxl (审核中...)

前往app查看评论内容

#NSCLC患者#

Radiology：术前脑MRI分期对IA期无症状NSCLC患者预后没有影响

2022-03-21

xiongliangxl (审核中...)

前往app查看评论内容

#NSCLC患者#

Oncologist：全球多中心真实世界探索EGFR-TKIs治疗罕见EGFR突变NSCLC患者的疗效

2022-03-16

xiongliangxl (审核中...)

前往app查看评论内容

#NSCLC患者#

Ther Adv Med Oncol：北京协和医院团队真实世界探索HER2改变的晚期NSCLC患者更佳一线治疗方案

2022-03-13

xiongliangxl (审核中...)

前往app查看评论内容

#NSCLC患者#

Target Oncol:吴一龙教授IIIb期研究关注近真实世界中afatinib(阿法替尼)治疗EGFR突变阳性NSCLC患者的疗效

2022-02-16

科室
- - 订阅+
  - 更多科室
工具
服务